Results 41 to 50 of about 43,399 (123)

New Pyridobenothiazolone Derivatives Display Nanomolar Pan‐Serotype Anti‐Dengue Virus Activity

ChemMedChem, EarlyView.
A ligand‐based strategy is employed, starting from hit compound 2, to develop the C‐2 modified pyridobenzothiazolone 19 as a pan‐serotype nanomolar DENV‐1‐4 inhibitor. Investigations of the mechanism reveal the peculiar ability to abolish the infectivity of virions in a second infection.
Tommaso Felicetti, Chin Piaw Gwee, Kitti Wing Ki Chan, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Satoru Watanabe, Muhammad Danial Bin Mohd Mazlan, Stefano Sabatini, Serena Massari, Oriana Tabarrini, Gianluca Sbardella, Subhash G. Vasudevan, Giuseppe Manfroni   +13 more
wiley   +1 more source

Novel Para‐Phenylenediamine‐Based Derivatives as Receptor Tyrosine Kinase‐like Orphan Receptor 1 (ROR1) Inhibitors: An In Vitro Preliminary Characterization

ChemMedChem, EarlyView.
ROR1 represents a promising target for the development of novel antiproliferative compounds, giving its high expression in different cancer cell lines. The present study describes the workflow leading to the design, synthesis, and characterization of a series of para‐phenylenediamine‐based compounds able to interact with the target kinase, inhibiting ...
Gerardina Smaldone, Maria Rosaria Miranda, Francesca Di Matteo, Valeria Napolitano, Michela Aliberti, Simona Musella, Veronica Di Sarno, Gianluigi Lauro, Giuseppe Bifulco, Giacomo Pepe, Giovanna Aquino, Mario Felice Tecce, Isabel Maria Gomez‐Monterrey, Pietro Campiglia, Carmine Ostacolo, Alessia Bertamino, Vincenzo Vestuto, Tania Ciaglia   +17 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

ESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer, Mauro Contini, Michele Emdin, Damiano Magrì, Alice Bonomi, Elisabetta Salvioni, Fabrizio Celeste, Alberico Del Torto, Claudio Passino, Christophe D.J. Capelle, Chiara Arzilli, Emiliano Fiori, Nicolò Capra, Christina Kronberger, Nikita Ermolaev, Andreas Kammerlander, Beatrice Musumeci, Giuseppe Vergaro, Vincenzo Castiglione, René Rettl, Giacomo Tini, Andrea Baggiano, Iacopo Fabiani, Susanna Sciomer, Roza Badr Eslam, Piergiuseppe Agostoni   +25 more
wiley   +1 more source

Global Functional Atlas of \u3cem\u3eEscherichia coli\u3c/em\u3e Encompassing Previously Uncharacterized Proteins [PDF]

, 2009
One-third of the 4,225 protein-coding genes of Escherichia coli K-12 remain functionally unannotated (orphans). Many map to distant clades such as Archaea, suggesting involvement in basic prokaryotic traits, whereas others appear restricted to E.
Ali, Mehrab, Babu, Mohan, Butland, Gareth, Chandran, Shamanta, Christopolous, Constantine, Emili, Andrew, Eroukova, Veronika, Golshani, Ashkan, Greenblatt, Jack F., Guao, Xinghua, Hu, Pingzhao, Janga, Sarah Chandra, Moreno-Hagelsieb, Gabriel, Musso, Gabriela, Nazarians-Armavil, Anaies, Nazemof, Nazila, Paccanaro, Alberto, Phanse, Sadhna, Pogoutse, Oxana, Wong, Peter, Yang, Wenhong   +20 more
core   +1 more source

Precision therapies for genetic epilepsies in 2025: Promises and pitfalls

Epilepsia Open, EarlyView.
Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang, Emilio Perucca, Samuel F. Berkovic, Piero Perucca   +3 more
wiley   +1 more source

Reimagining pharmacy processes for expanding hospital at‐home care in Singapore: A qualitative study

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, EarlyView.
Abstract Introduction Mobile Inpatient Care at Home (MIC@Home) is an alternative acute care model that offers care within patients' homes instead of in traditional hospital settings. This qualitative study seeks to investigate existing perspectives on MIC@Home and the challenges associated specifically with its provision of pharmacy services, and ...
Brian Lee, Hazel Syn, Valerie Ng, Yi Feng Lai   +3 more
wiley   +1 more source

Race, Money and Medicines [PDF]

, 2006
Taking notice of race is both risky and inevitable, in medicine no less than in other endeavors. The literature on race as a classifying tool in clinical research poses this core dilemma: On the one hand, race can be a useful stand-in for unstudied ...
Bloche, Maxwell Gregg
core   +1 more source

In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma. [PDF]

, 2016
The long-term overall survival of Ewing sarcoma (EWS) patients remains poor; less than 30% of patients with metastatic or recurrent disease survive despite aggressive combinations of chemotherapy, radiation and surgery.
Alturkmani, Hani, Baltezor, Michael, Butte, Atul J, Chen, Bin, Flynn, Colleen A, Godwin, Andrew K, Hyter, Stephen, Ma, Yan, Neville, Kathleen A, Pessetto, Ziyan Y, Rosenthal, Howard G, Weir, Scott J   +11 more
core   +3 more sources

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, EarlyView.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act [PDF]

With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity.
Frank R. Lichtenberg, Joel Waldfogel
core